Related references
Note: Only part of the references are listed.Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity
Alexander Juto et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Pregnancy-related relapses and breastfeeding in a contemporary multiple sclerosis cohort
Annette Langer-Gould et al.
NEUROLOGY (2020)
Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis
M. Boremalm et al.
EUROPEAN JOURNAL OF NEUROLOGY (2019)
Comparative effectiveness of rituximab relative to IFN- or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry
Tim Spelman et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis
Ingrid Meinl et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Comparative effectiveness of rituximab relative to IFN- or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry
Tim Spelman et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis
Ingrid Meinl et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis
Mathias Granqvist et al.
JAMA NEUROLOGY (2018)
Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis
Ivan Jelcic et al.
CELL (2018)
Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis
David Baker et al.
EBIOMEDICINE (2017)
Rituximab versus Fingolimod after Natalizumab in Multiple Sclerosis Patients
Peter Alping et al.
ANNALS OF NEUROLOGY (2016)
Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab
Pierre de Flon et al.
NEUROLOGY (2016)
Rituximab in multiple sclerosis A retrospective observational study on safety and efficacy
Jonatan Salzer et al.
NEUROLOGY (2016)
Subgroups of multiple sclerosis patients with larger treatment benefits: a meta-analysis of randomized trials
A. Signori et al.
EUROPEAN JOURNAL OF NEUROLOGY (2015)
A changing treatment landscape for multiple sclerosis: challenges and opportunities
F. Piehl
JOURNAL OF INTERNAL MEDICINE (2014)
Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis
Ilana Katz Sand et al.
MULTIPLE SCLEROSIS JOURNAL (2014)
Intense Inflammation and Nerve Damage in Early Multiple Sclerosis Subsides at Older Age: A Reflection by Cerebrospinal Fluid Biomarkers
Mohsen Khademi et al.
PLOS ONE (2013)
Immune Reconstitution Inflammatory Syndrome in Patients With Multiple Sclerosis Following Cessation of Natalizumab Therapy
Augusto Miravalle et al.
ARCHIVES OF NEUROLOGY (2011)
Anti-CD20 therapy in patients with rheumatoid arthritis -: Predictors of response and B cell subset regeneration after repeated treatment
Petra Roll et al.
ARTHRITIS AND RHEUMATISM (2008)
Relapses in multiple sclerosis are age- and time-dependent
H. Tremlett et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2008)
B-cell depletion with Rituximab in relapsing-remitting multiple sclerosis
Stephen L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Age-related gadolinium-enhancement of MRI brain lesions in multiple sclerosis
C Tortorella et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2005)
Share Paper
